Imatinib mesylate: a new pill for chronic myelogenous leukemia

Cancer Pract. 2001 Sep-Oct;9(5):263-5. doi: 10.1046/j.1523-5394.2001.95003.x.

Authors

K K Parmar¹, R S King

Affiliation

¹ Department of Pharmacy Services, Temple University Hospital, Philadelphia, Pennsylvania, USA.

PMID: 11879324
DOI: 10.1046/j.1523-5394.2001.95003.x

No abstract available

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / pharmacokinetics
Antineoplastic Agents / therapeutic use*
Benzamides
Clinical Trials as Topic
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Piperazines / adverse effects
Piperazines / pharmacokinetics
Piperazines / therapeutic use*
Pyrimidines / adverse effects
Pyrimidines / pharmacokinetics
Pyrimidines / therapeutic use*

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate